While PD-L1 tumor/stromal expression is a currently used predictive biomarker, it is not highly accurate at predicting response to anti PD-1 therapies, as PD-L1 is a dynamic immune modulating biomarker that can change over time and upregulate in certain treatment types13. This evidence concerns the gene CD274 and neoplasm.